AlbuCORE: an albumin-based molecular scaffold for multivalent biologics design.
AlbuCORE
Albumin
HSA
Human serum albumin
biologics
drug conjugate
multispecific
multivalent
non-antibody scaffold
therapeutic scaffold
Journal
mAbs
ISSN: 1942-0870
Titre abrégé: MAbs
Pays: United States
ID NLM: 101479829
Informations de publication
Date de publication:
Historique:
entrez:
21
8
2020
pubmed:
21
8
2020
medline:
6
7
2021
Statut:
ppublish
Résumé
As biologics have become a mainstay in the development of novel therapies, protein engineering tools to expand on their structural advantages, namely specificity, affinity, and valency are of interest. Antibodies have dominated this field as the preferred scaffold for biologics development while there has been limited exploration into the use of albumin with its unique physiological characteristics as a platform for biologics design. There has been a great deal of interest to create bispecific and more complex multivalent molecules to build on the advantages offered by protein-based therapeutics relative to small molecules. Here, we explore the use of human serum albumin (HSA) as a scaffold for the design of multispecific biologics. In particular, we describe a structure-guided approach to the design of split HSA molecules we refer to as AlbuCORE, that effectively and spontaneously forms a native albumin-like molecule, but in a heterodimeric state upon co-expression. We show that the split AlbuCORE designs allow the creation of novel fusion entities with unique alternate geometries. We also show that, apart from these AlbuCORE fusion entities, there is an opportunity to explore their albumin-like small hydrophobic molecule carrying capacity as a drug conjugate in these designs.
Identifiants
pubmed: 32816577
doi: 10.1080/19420862.2020.1802188
pmc: PMC7531512
doi:
Substances chimiques
Serum Albumin, Human
ZIF514RVZR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Pagination
1802188Références
Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1915-20
pubmed: 15684082
Nature. 2003 Feb 13;421(6924):756-60
pubmed: 12610629
Cancer Chemother Pharmacol. 2015 Oct;76(4):699-712
pubmed: 26231955
Gastroenterology. 2010 Oct;139(4):1267-76
pubmed: 20600017
Mol Cancer Ther. 2012 Mar;11(3):582-93
pubmed: 22248472
Nat Commun. 2016 Jun 03;7:11672
pubmed: 27255951
Gastroenterology. 2010 Oct;139(4):1257-66
pubmed: 20600013
Clin Cancer Res. 2013 Oct 15;19(20):5572-9
pubmed: 23918602
Structure. 2013 Nov 5;21(11):1966-78
pubmed: 24120761
Acc Chem Res. 2000 Dec;33(12):889-97
pubmed: 11123888
Arch Biochem Biophys. 2012 Oct 15;526(2):219-25
pubmed: 22426455
MAbs. 2015;7(3):571-83
pubmed: 25875452
Cancer Immunol Immunother. 2008 Dec;57(12):1879-90
pubmed: 18408925
Structure. 2013 Nov 5;21(11):1979-91
pubmed: 24095059
Oncotarget. 2017 Jan 10;8(2):3528-3541
pubmed: 27974681
Nat Med. 2017 Feb;23(2):235-241
pubmed: 28024083
J Mol Biol. 2000 Nov 10;303(5):721-32
pubmed: 11061971
Mol Aspects Med. 2012 Jun;33(3):209-90
pubmed: 22230555
Sci Am. 1994 Jul;271(1):58-65
pubmed: 8066425
Biotechnol Prog. 2015 Jan-Feb;31(1):62-9
pubmed: 25270911
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Semin Cell Dev Biol. 2010 Feb;21(1):55-65
pubmed: 19958839
Front Immunol. 2018 Jan 04;8:1751
pubmed: 29379493
J Biomed Sci. 2020 Jan 2;27(1):1
pubmed: 31894001
J Med Chem. 2014 Aug 28;57(16):6949-64
pubmed: 24967516
J Clin Endocrinol Metab. 2008 Dec;93(12):4810-7
pubmed: 18812476
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3294-9
pubmed: 19218427
Signal Transduct Target Ther. 2017 May 19;2:17015
pubmed: 29263918
Cancer Res. 2017 Nov 1;77(21):5925-5937
pubmed: 28923854
J Mol Biol. 1996 Nov 8;263(4):551-67
pubmed: 8918938
Cancer Cell. 2016 Jan 11;29(1):117-29
pubmed: 26766593
Cancer. 2007 Jan 15;109(2):170-9
pubmed: 17154393
MAbs. 2015;7(2):344-51
pubmed: 25654695
J Biotechnol. 2016 Jun 10;227:103-111
pubmed: 27085888
Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):208-13
pubmed: 25535368
Nature. 2014 Mar 27;507(7493):519-22
pubmed: 24531764
Cell Mol Life Sci. 2008 Apr;65(7-8):1059-72
pubmed: 18080088
Cancer Res. 2007 Jan 1;67(1):254-61
pubmed: 17210705
Cancer Cell. 2004 Apr;5(4):317-28
pubmed: 15093539
J Control Release. 2016 Feb 10;223:22-30
pubmed: 26699424
Trends Pharmacol Sci. 2016 Dec;37(12):993-1008
pubmed: 27836202
J Mol Biol. 2012 Sep 28;422(4):532-44
pubmed: 22706026
Antibodies (Basel). 2017 Sep 01;6(3):
pubmed: 31548527
Antibodies (Basel). 2017 May 16;6(2):
pubmed: 31548523
MAbs. 2013 Sep-Oct;5(5):646-54
pubmed: 23924797
Front Immunol. 2015 Jan 26;5:682
pubmed: 25674083
J Struct Biol. 2010 Sep;171(3):353-60
pubmed: 20347991
J Mol Biol. 1996 Jan 12;255(1):28-43
pubmed: 8568873
Trends Pharmacol Sci. 2008 Feb;29(2):57-61
pubmed: 18179828
Oncogenesis. 2016 Feb 22;5:e200
pubmed: 26900952
Crit Rev Oncol Hematol. 1997 Jul;26(2):77-100
pubmed: 9298326
Nature. 2013 May 30;497(7451):633-7
pubmed: 23665962
Biochim Biophys Acta. 2013 Dec;1830(12):5351-3
pubmed: 24094116
J Biol Chem. 1977 Jun 25;252(12):4326-9
pubmed: 325004
Front Physiol. 2014 Aug 12;5:299
pubmed: 25161624
Adv Drug Deliv Rev. 2011 Mar 18;63(3):129-30
pubmed: 20457195
J Exp Med. 2003 Feb 3;197(3):315-22
pubmed: 12566415
Biochemistry. 2005 Dec 6;44(48):15705-14
pubmed: 16313173
Can J Gastroenterol Hepatol. 2018 Feb 12;2018:1863535
pubmed: 29623263
J Biol Chem. 2014 May 9;289(19):13492-502
pubmed: 24652290
J Biol Chem. 2014 Mar 14;289(11):7812-24
pubmed: 24469444
Future Oncol. 2017 Feb;13(5):455-467
pubmed: 27578614
MAbs. 2017 Feb/Mar;9(2):182-212
pubmed: 28071970
Front Oncol. 2013 Jul 26;3:193
pubmed: 23898462
Cell Death Differ. 2016 May;23(5):733-47
pubmed: 26943322